Visual results after implantation of a trifocal intraocular lens in high myopes

Session Details

Session Title: Cataract
Session Date/Time: Saturday 10/02/2018 | 08:30-11:00
Paper Time: 10:18
Venue: Blue Hall

First Author: G.Steinwender AUSTRIA
Co Author(s): L. Schwarz  M. Boehm  E. Hemkeppler  A. Slavik-Lencova  M. Shajari  T. Kohnen  

Abstract Details

Purpose:

To report visual and refractive outcomes after implantation of a trifocal intraocular lens (IOL) in highly myopic patients.

Setting:

Department of Ophthalmology, Goethe-University, Frankfurt, Germany

Methods:

This retrospective cohort study included eyes with previous phacoemulsification and implantation of a trifocal IOL (AT LISA tri 839MP/939MP; Carl Zeiss Meditec, Jena, Germany) with an IOL power between 0 and 10 diopters (D). Postoperative outcomes at 3 months including uncorrected distance (UDVA), intermediate (UIVA) and near visual acuity (UNVA), corrected distance visual acuity (CDVA), spherical equivalent, and refractive astigmatism were analyzed. Age-matched eyes after implantation of the same trifocal IOL with higher dioptric power (> 10 D) served as controls.

Results:

Thirty-six eyes of 19 patients were included; 18 eyes (10 patients) in the highly myopic group (IOL power 0 to 10 D), and 18 eyes (9 patients) in the age-matched control group (IOL power > 10 D). Three months postoperatively, mean UDVA, UIVA and UNVA in the highly myopic group were 0.06 ± 0.08 logMAR, 0.13 ± 0.09 logMAR, and 0.12 ± 0.07 logMAR, and -0.01 ± 0.10 logMAR, 0.04 ± 0.10 logMAR, and 0.04 ± 0.11 logMAR in the control group (P = 0.022, P = 0.033, P = 0.053, respectively), respectively.

Conclusions:

Implantation of a trifocal IOL in highly myopic eyes with low IOL power (0 to 10 D) provides satisfactory visual and refractive outcomes. However, results were not as good as those obtained in eyes with higher dioptric IOL power.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, , research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented